Addition of adult-to-adult living donation to liver transplant programs improves survival but at an increased cost by Northup, Patrick G. et al.
ORIGINAL ARTICLE
Addition of Adult-to-Adult Living Donation to
Liver Transplant Programs Improves Survival but
at an Increased Cost
Patrick G. Northup,1 Michael M. Abecassis,2 Michael J. Englesbe,3 Jean C. Emond,4 Vanessa D. Lee,1
George J. Stukenborg,1,5 Lan Tong,3 Carl L. Berg,1 and the Adult-to-Adult Living Donor
Liver Transplantation Cohort Study Group
1Department of Medicine, University of Virginia, Charlottesville, VA; 2Department of Surgery, Northwestern
University, Chicago, IL; 3Department of Surgery, University of Michigan, Ann Arbor, MI; 4Department of
Surgery, Columbia University College of Physicians and Surgeons, New York, NY; and 5Department of
Health Sciences, University of Virginia, Charlottesville, VA
Using outcomes data from the Adult-to-Adult Living Donor Liver Transplantation Cohort Study, we performed a cost-
effectiveness analysis exploring the costs and benefits of living donor liver transplantation (LDLT). A multistage Markov
decision analysis model was developed with treatment, including medical management only (strategy 1), waiting list with
possible deceased donor liver transplantation (DDLT; strategy 2), and waiting list with possible LDLT or DDLT (strategy 3) over
10 years. Decompensated cirrhosis with medical management offered survival of 2.0 quality-adjusted life years (QALYs) while
costing an average of $65,068, waiting list with possible DDLT offered 4.4-QALY survival and a mean cost of $151,613, and
waiting list with possible DDLT or LDLT offered 4.9-QALY survival and a mean cost of $208,149. Strategy 2 had an incremental
cost-effectiveness ratio (ICER) of $35,976 over strategy 1, whereas strategy 3 produced an ICER of $106,788 over strategy
2. On average, strategy 3 cost $47,693 more per QALY than strategy 1. Both DDLT and LDLT were cost-effective compared
to medical management of cirrhosis over our 10-year study period. The addition of LDLT to a standard waiting list DDLT
program is effective at improving recipient survival and preventing waiting list deaths but at a greater cost. Liver Transpl 15:
148-162, 2009. © 2009 AASLD.
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Living donor liver transplantation (LDLT) is an alterna-
tive to traditional deceased donated transplants, but
there is little reliable outcomes data for adult-to-adult
LDLT on which to base clinical decisions, patient coun-
seling, or health policy. Of primary concern, the expo-
sure to potential donor morbidity and mortality has not
been evaluated, and case series reported in the litera-
ture vary in claims of donor morbidity in the immediate
perioperative period from minimal1 to 18%.2,3 Although
analyses of costs,4-9 outcomes,1,2,10-12 and quality of
life13-22 in relation to LDLT have been published, few
have evaluated the true cost effectiveness of LDLT with
a formal medical decision analysis.23-26 Previously
published studies were also hindered by a lack of ac-
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curate data with respect to donor outcomes and incom-
plete accounting of donor morbidity.
In the year 2000, the US National Institutes of Health
organized a multicenter prospective cohort study of
adult-to-adult LDLT performed at several large trans-
plant centers in the United States over a 5-year peri-
od.27,28 This cohort study has been given the name
Adult-to-Adult Living Donor Liver Transplantation Co-
hort Study (A2ALL). When completed in 2009, the study
will report all significant surgical and clinical outcomes
for adult-to-adult LDLT candidates, recipients, and do-
nors at 9 major transplant centers in the United States.
This data assessment by the A2ALL consortium is the
largest and most current systematic report of the LDLT
experience in the United States and includes outcomes
from 819 transplant candidates, 1011 potential living
donors, and 392 successful living donors. The aim of
the current study is to evaluate the cost effectiveness of
adult-to-adult LDLT versus deceased donor liver trans-
plantation (DDLT) using the most comprehensive and
current data on variables such as donor morbidity and
mortality, complication events, and quality-of-life esti-
mates derived from A2ALL, the United Network for Or-




Cost-effectiveness analysis using Markov models has
been described elsewhere.29 The model developed for
this simulation considers 6 health states that can occur
for patients with end-stage liver disease any time over a
10-year time horizon, including the pretransplantation,
perioperative, and posttransplant time periods. Figure
1 graphically displays the health states and transitions
represented in the model. The model provides a concep-
tual framework for organizing the relationship of events
and costs and the utility of different outcomes for pa-
tients with end-stage liver disease.
Three separate treatment strategies are simulated in
the model: (1) supportive care/medical management
only for decompensated liver disease, (2) standard
Model for End-Stage Liver Disease–based wait listing
for DDLT, and (3) DDLT wait listing in addition to an
evaluation of prospective donors for LDLT. A Monte
Carlo simulation of the Markov decision model was
used to estimate the distribution of events that would
occur for 1000 subjects (cohort members) over 10
years. All event probabilities in the model were calcu-
lated with a 1-month cycle length, which was selected
as the most clinically pertinent time increment to sim-
ulate chronic liver disease and transplantation events.
Half-cycle corrections were included (except for the first
and last cycles) to account for mid-cycle cost and utility
accumulation.29 In the model, members cycle through
1 of 6 basic health states, as shown in Fig. 1. By defi-
nition, every candidate entering the model is referred
for transplantation with a potential living donor avail-
able for assessment. Patients can remain compensated
on the waiting list or can have various complications of
cirrhosis, including esophageal variceal bleeding, hep-
atocellular carcinoma (HCC), and ascites flare. When
these acute events resolve, they are returned to the
theoretical stable waiting list after appropriate costs
and utility tolls are assigned for the events. A similar
construct of a stable health state interrupted by com-
plications is used in the posttransplant section of the
model. To account for inflation, all costs are repre-
sented in adjusted year 2002 US dollars. All utilities
and costs are discounted by 3% yearly in order to ac-
count for the decreased present value of future costs
and benefits.30 Data for Healthcare, version 3.5 (Tree-
Age Software, Williamstown, MA), was used for model-
ing, and SAS, version 9.1 (Cary, NC), was used for
statistical analysis and dataset manipulation. The Uni-
versity of Virginia Institutional Review Board for Hu-
man Research approved this study.
Event Probabilities
All major events in the pretransplant, peritransplant,
and posttransplant treatment of cirrhosis were mod-
eled. Table 1 lists the baseline estimates for event prob-
abilities used in the model, the range of values used for
sensitivity analysis, and the sources of the data. LDLT
events, especially those related to donor complications,
were derived from the A2ALL dataset when available. A
complete description of the A2ALL cohort patient pop-
ulation is published elsewhere.31 DDLT event probabil-
ities were drawn from data supplied by the UNOS trans-
plant registry.32 The UNOS supplied database, the
Standard Transplant Analysis and Research (STAR)
data set, was queried to calculate actual event rates
and distributions that occurred during all adult liver
transplants between January 1, 1999 and November
16, 2003. A complete population description of the
STAR data set is outlined at www.unos.org or www.us-
transplant.org. Base case probabilities were derived
Figure 1. The basic health states of the Markov model. Ab-
breviations: DDLT, deceased donor liver transplantation;
LDLT, living donor liver transplantation.
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Yearly percent chance of developing symptomatic ascites on waitlist 20.3% 10%-40% 32, 72, 73
Percent chance of receiving TIPS for ascites or bleeding 20.5% 5%-40% 32, 72, 74
Percent chance of death related to each TIPS procedure 3.8% 1%-8% 72, 74
Yearly percent chance of contracting SBP in patients with
symptomatic ascites
4.3% 2%-8% 72, 75-78
Percent chance of death related to each episode of SBP 20.0% 10%-40% 72, 75, 77-79
Yearly percent chance of having encephalopathy requiring
admission
23.5% 11%-46% 32, 80
Percent chance of death from each episode of encephalopathy 11.5% 5%-25% 81, 82
Yearly percent chance of developing HCC on waitlist 10.3% 5%-20% 32, 83
Yearly percent chance in patients with HCC of progression
resulting in delisting (equivalent to 5.4% per 90 days on the
waiting list)
21.7% 10%-40% 32, 84
Yearly percent chance of variceal hemorrhage 22.4% 11%-44% 32, 85-87
Percent chance of death from each episode of variceal hemorrhage 14.2% 7%-28% 86-88
Yearly percent chance of remaining stable on waitlist, without
complications
18.7% 9%-36% 89




Percent chance of DDLT recipient death within 30 days of
transplant
4.1% 2%-9% 32, 94, 95
Percent chance of graft failure due to disease recurrence 2.0% 1%-10% 32
Percent chance of successful retransplantation in patient with graft
failure secondary to recurrent disease
24.9% 12%-50% 32
Yearly percent chance of admission for nonbiliary sepsis post-DDLT 9.9% 4%-20% 96-98
Percent chance of death from each sepsis event after DDLT 14.1% 7%-28% 96-98
Percent chance of needing nontransplant, no-biliary reoperation
more than 30 days after DDLT
22.5% 11%-45% 99
Percent chance of death after each nontransplant reoperation after
DDLT
10.5% 1%-20% 99
Percent chance of a biliary complication after DDLT 21% 10%-40% 100-104
Probability of death from biliary complications after DDLT 4.7% 2%-9% 100, 101, 104, 105
Percent chance of receiving retransplantation in a recipient with
biliary complications after DDLT
4.8% 2%-9% 102, 106, 107
Percent chance of requiring nontransplant reoperation in a
recipient with biliary complications after DDLT
8.0% 4%-16% 100, 102, 104, 108
Percent chance of acute rejection severe enough for hospitalization
after DDLT
35.9% 15%-60% 11, 109, 110
Percent chance of death from an episode of acute rejection after
DDLT
0.2% 0.1-0.5% 110
Percent chance of requiring retransplantation because of severe




Probability of donor death after LDLT procedure 0.28% 0.01%-1% 51-55
Probability of donor having major complications (Clavien grade 3
or 4) after LDLT procedure
1.5% 0.5%-4% A2ALL,52-54, 56,
57, 111-116
Probability of donor having minor or major complications (Clavien
grade 2 or greater) after LDLT procedure
13% 6%-25% 52-54, 56, 57,
111-116
Recipient
Percent chance of LDLT recipient death within 30 days of
transplant
4.6% 2%-9% A2ALL, 31, 32, 117
Percent chance of graft failure due to disease recurrence 3.2% 1.5%-7% A2ALL, 31, 118-
122
Percent chance of successful retransplantation in patient with
graft failure secondary to recurrent disease
21.4% 12%-50% A2ALL, 32
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from exact calculations when they were available from
the UNOS data set or from A2ALL data. When exact
calculations were not available, data were abstracted
from the literature. In a few cases, mainly the compli-
cations of cirrhosis in the pretransplant phase, enough
data were available from the literature to calculate
weighted averages for probabilities. When none of these
choices were available, a point prevalence or percentage
was used based on the published literature. Sensitivity
margins attempted to encompass the span of the avail-
able literature on the event.
Financial Costs
All costs represented in the model are based on the
medical center cost point of view. All direct and indirect
outpatient and inpatient costs accrued over the 10-year
study period are accounted for in the model. Abstract
costs such as lost wages and emotional costs are not
measured in this model. Accurate, easily generalized
liver transplantation cost data were not available from
the literature, A2ALL data set, or the STAR data set.
Cost data for this analysis were obtained from mean
values derived from liver transplant patient hospitaliza-
tions and physician administrative data abstracted
from the University of Virginia Health System Clinical
Data Repository (CDR).33 The CDR is a secure compre-
hensive clinical database that captures all inpatient
and outpatient clinical contacts in the University of
Virginia Health System. The CDR uses microcosting
algorithms to capture extensive cost data in an actual
utilization (non–diagnosis-related group) framework.
Financial transactions are recorded in the CDR as both
third-party charges and actual costs and are calculated
with real-time discharge utilization algorithms. The de-
velopment, accuracy, and validity of the University of
Virginia CDR have been published elsewhere.34-37 Cost
data from the CDR have been used successfully in other
decision analysis models and publications, and costs
calculated with the CDR have been shown to be com-
parable to adjusted national costs.38 Table 2 shows the
estimated cost data components for the model.
Health-Related Utility Measures
Health outcomes research and health decision analysis
depend on analyzing not only the length of time spent in
a health state but also the quality of life, or utility,
associated with that state. Quantification of this level of
sickness and the prorating of years of life spent in ill-
ness (compared to perfect health) enables a decision
analysis to best quantify survival and standardize qual-
ity of life in order to more accurately compare medical






Yearly percent chance of recipient admission for nonbiliary sepsis
post-LDLT
9.9% 4%-20% A2ALL, 31, 96-98
Percent chance of recipient death from each sepsis event after
LDLT
14.5% 7%-28% A2ALL, 31, 96-98
Percent chance of recipient requiring nontransplant, nonbiliary
reoperation after LDLT
22.5% 11%-45% A2ALL, 31, 51, 112
Percent chance of recipient death after each nontransplant
reoperation after LDLT
10.5% 1%-20% 99
Percent chance of a recipient biliary complication after LDLT 37% 15%-60% A2ALL, 31, 51,
104, 108, 117,
123, 124
Percent chance of recipient death from biliary complications after
LDLT
9.7% 4%-19% A2ALL, 31, 100,
101, 104, 108,
117, 123, 124
Percent chance of receiving retransplantation in a recipient with
biliary complications after LDLT
4.9% 2%-10% 100, 101, 104,
117, 123, 124
Percent chance of requiring nontransplant reoperation in a
recipient with biliary complications after LDLT
54.9% 20%-90% A2ALL,104, 117,
123, 124
Chance of having acute rejection severe enough for
hospitalization after LDLT
33.9% 15%-60% A2ALL, 11, 109,
110, 122, 125
Percent chance of death from an episode of acute rejection after
LDLT
0.2% 0.1-0.5% A2ALL, 11, 110,
122, 125
Percent chance of requiring retransplantation because of
rejection after LDLT
1.3% 0.5%-3% A2ALL, 11, 110,
122, 125
Abbreviations: A2ALL, Adult-to-Adult Living Donor Liver Transplantation Cohort Study; DDLT, deceased donor liver
transplantation; HCC, hepatocellular carcinoma; LDLT, living donor liver transplantation; SBP, spontaneous bacterial
peritonitis; TIPS, transjugular intrahepatic portosystemic shunt.
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TABLE 2. Cost Data Used in the Model
Monthly
Costs Monthly Cost Range*
Baseline health state costs
Baseline average monthly outpatient costs for patients with
compensated cirrhosis
63 31-126
Baseline average monthly costs for subjects with permanent
contraindication to transplant
777 389-1554
Baseline average monthly costs for recipients post-
transplantation
772 386-1544
Cost tolls for specific events
Average cost of TIPS procedure (includes revisions, complications,
hospitalizations, imaging, and outpatient follow-up)
18,192 9096-36,384
Average cost of an episode of SBP (includes treatment,
hospitalization, complications, and imaging)
10,248 5124-20,496
Average cost of ascites and peripheral edema requiring admission
to the hospital
6,197 3,098-12,394
Average cost of encephalopathy admission 4,297 2,148-8,594
Average monthly cost of HCC (includes imaging, procedures, and
follow-up)
3,755 1,877-7,510
Average cost of variceal bleeding (includes hospitalization,
procedures, and follow-up)
11,964 5,892-23,928
One-time cost of DDLT procedure (includes deceased donor
expenses and organ acquisition costs from OPO,
hospitalization, and pharmacy126)
103,806 51,903-207,612
One-time cost of LDLT procedure [includes workup costs for 1.23
potential donors,49,50 donor procedure without complications,
hospitalization, and pharmacy126; donor costs are normalized
to DDLT OPO charges to avoid double-charging living donors;
the actual estimated costs for a 1-time live donor procedure
without complications is $129,144]
103,806 51,903-207,612
One-time cost for donor having major complications (includes
hospitalization, procedures, pharmacy, and follow-up)
16,892 8,446-33,784
One-time cost for donor death (estimated at 75% of the cost of a
major complication)
12,669 6,335-25,338
One-time cost for recurrent disease causing graft failure (this is
applied only to subjects not eligible for retransplantation; based
on costs incurred for care when transplant is contraindicated)
4,662 2,331-9,324
Average cost for posttransplant subjects with nonbiliary
infectious complications (includes hospitalization, imaging,
pharmacy, and follow-up)
6,952 3,476-13,904
Average cost for posttransplant recipients that require
nontransplant reoperation (based on the cost of laparotomy)
16,892 8,446-33,784
Average cost for posttransplant subjects with clinically significant
biliary complications (includes cost associated with chronic
biliary strictures, and 2 ERCPs104)
7,292 3,646-14,584
One-time cost of posttransplant recipients that require
nontransplant reoperation for biliary complication (does not
include ERCP costs; based on the cost of laparotomy)
18,607 9,303-37,214
Average cost of posttransplant treatment of acute rejection
(includes hospitalization, procedures, pharmacy, and follow-up)
6,798 3,339-13,596
NOTE: All costs are reported in year 2002 adjusted US dollars. See the text for the derivation of the costs.
Abbreviations: DDLT, deceased donor liver transplantation; ERCP, endoscopic retrograde cholangiopancreatography; HCC,
hepatocellular carcinoma; LDLT, living donor liver transplantation; OPO, organ procurement organization; SBP, spontaneous
bacterial peritonitis; TIPS, transjugular intrahepatic portosystemic shunt.
*Ranges are derived as 50% and 200% of the calculated costs.
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state utilities associated with chronic liver disease and
liver transplantation derived by standardized and vali-
dated methods.40-47 Table 3 lists the utility values for
the health states in the model and specific event-related
utility tolls, or penalties, for adverse events in the
model.
Donor Complications and Costs
Previously published models of LDLT have not ade-
quately accounted for donor morbidity, mortality, or
costs.25,26,48 Evidence from the literature indicates that
prospective donors are frequently disqualified from the
donation process following discovery of preexisting
medical conditions or tissue incompatibilities or by
their eventual unwillingness to participate.49,50 Donor
death and serious morbidity significantly affect the
overall utility and costs of the LDLT process. The prob-
ability of these events is uncertain, but is becoming
clearer as the published literature on donor complica-
tions expands.51-55
Living donor costs are not well accounted for in the
current reimbursement system in the United States,
and there is little published data on this topic. We
performed an informal multicenter survey regarding
the costs and charges assigned to the living donor in
LDLT. It was generally agreed that typical costs paid to
the organ procurement organization (OPO) for DDLT
should not be attributed to the living donor. A detailed
analysis at 2 of the A2ALL centers showed that the
costs attributed to the living donor approximate the
costs paid to the OPO for DDLT (unpublished data).
Many of the centers, for accounting purposes, assigned
a cost to the LDLT recipient that was equal to the OPO
charges for DDLT. Therefore, we chose to equalize the
costs for the hospitalizations of the living donor to the
OPO DDLT costs in the model. This resulted in only a
small difference for the actual DDLT and LDLT hospi-
talizations. Repeated trial runs of the model with both
the equalized costs and the individual estimated costs
for both procedures yielded nearly the exact same re-
sults (see Table 2). Thus, we chose to use the most
common accounting practice in the final model. A wide
variation was used in the sensitivity analysis to test the
impact of this decision.
Our model assumes that all living donors enter the
simulation in a state of perfect health. On the basis of
the A2ALL experience, for each LDLT recipient, 1.23
prospective donors are evaluated. This accounts for the
extra cost of evaluating donors that are eventually
deemed ineligible.49,50 Variables were introduced into
the model in order to account for differential rates of
major complications between LDLT and DDLT and the
various costs associated with these complications. The
major complication rates for donors were extracted
from the A2ALL data set and include all donor compli-
TABLE 3. Utility Data Used in the Model
Baseline Health State Utility Base Case Utility Utility Range Sources
Utility of compensated cirrhosis (Child B) 0.71 0.44-0.98 40-47
Utility of decompensated cirrhosis (Child C) 0.56 0.30-0.67 40-47
Utility of recipient post–liver transplantation 0.80 0.63-0.87 41, 43, 45, 47, 127
Utility penalty accrued every month after transplant
when donor dies secondary to donation complication





Utility penalty accrued every month after transplant
when donor has major complications secondary to
donation complication128 (donors are assumed to be




Utility Toll for Specific Events Percent Toll from
Baseline
Range Sources
Monthly utility penalty for refractory ascites 25% 0%-80% 44
One-time utility penalty from TIPS 25% 0%-80% 42
One-time utility penalty for SBP (based on utility for
refractory ascites)
25% 0%-80% 44
Monthly utility penalty for HCC 10% 0%-50% 41, 43, 44
Monthly utility penalty for encephalopathy 25% 0%-80% 42, 44
Monthly utility penalty for variceal bleeding 25% 0%-80% 42, 44
One-time utility penalty for recent major surgery 20% 0%-80% 58
Monthly utility penalty for major complication of
transplantation
25% 0%-80% 41, 43, 45, 47, 127
One-time utility penalty for undergoing DDLT 50% 25%-75% 41, 43, 45, 47, 127
One-time utility penalty for undergoing LDLT (includes
combined donor and recipient penalties)
75% 25%-90% 41, 43, 45, 47, 127, and
expert opinion
Abbreviations: DDLT, deceased donor liver transplantation; HCC, hepatocellular carcinoma; LDLT, living donor liver
transplantation; SBP, spontaneous bacterial peritonitis; TIPS, transjugular intrahepatic portosystemic shunt.
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cations considered grade 3 or above according to the
Clavien grading system.3,56,57 Donor deaths incur a
penalty of 1.0 utility point per month for the remainder
of the simulation. Donor severe complications incur a
penalty of 0.30 utility points per month for the remain-
der of the simulation. This is based on the documented
health utility after complications from major surgery.58
Donor utility penalties continue to accrue for the re-
mainder of the simulation in order to account for the
loss of life for the donor who has died or the loss of
quality of life for donors who suffer a major complica-
tion.
Sensitivity Analysis
The cost-effectiveness analysis results were assessed
for sensitivity to each of the individual estimated prob-
abilities, costs, and utilities in the model. The ranges of
minimum and maximum values considered for each
estimated component in the model are shown in the
tables of the model probabilities, costs, and utilities.
RESULTS
Model Validation and Unadjusted Recipient
Survival
Table 4 lists results from the Monte Carlo simulation of
the Markov decision analysis model iterating 1000 the-
oretical subjects with decompensated cirrhosis. Ten-
year posttransplant survival rates for DDLT recipients
(542 of 687, 79.0%) and LDLT recipients (510 of 715,
71.3%) were comparable to reported survival rates in
the literature. The 10-year survival rate for subjects
with no access to transplantation (3.6%) was compara-
ble to that reported in the literature for end-stage liver
disease. The mean waiting time for all candidates was
149 days, which is comparable to the current waiting
times for DDLT in the United States. The LDLT simula-
tion yielded 2 donor deaths (0.2%) and 17 major com-
plications in donors (2.4%). The maximum survival was
attained in the LDLT-exposed treatment branch. In this
branch, there were 715 LDLT and 233 DDLT proce-
dures with 112 subjects (11.2%) dying on the waitlist
and 285 subjects (28.5%) dying after transplantation.
This treatment branch terminated at 10 years with 24
subjects still alive and awaiting transplantation.
The major contributor to the increased 5-year sur-
vival rate in the LDLT-exposed treatment arm com-
pared to the DDLT-only treatment arm was the
decreased number of subjects dying on the waiting
list. The DDLT-only treatment arm had a 30.9% mor-
tality rate on the waiting list, whereas the LDLT treat-
ment arm had 11.2% waitlist mortality over the 10
years of the simulation. This yielded a relative risk of
waitlist mortality of 2.75 in the DDLT-only group com-
pared to the LDLT-exposed group with a relative risk
reduction for waitlist death of 63.8%. This is equivalent
to a number needed to treat of 5 to prevent 1 waitlist
death; that is, for every 5 patients listed at a transplant
program with access to LDLT, 1 waitlist death was pre-
vented in comparison with programs with only DDLT
access. This finding is in agreement with previously
published recipient survival improvements afforded by
LDLT.59,60






Listed for DDLT with
LDLT Available
Mean cost per patient (2002 US dollars) 65,068 151,613 208,149
Mean unadjusted lifespan (years) 3.1 6.4 7.3
Mean quality-adjusted lifespan (QALYs) 1.9 4.4 4.9
Number receiving DDLT (primary or retransplant) — 687 233
Number receiving LDLT (primary) — — 715
Number dead after 1 year 175 158 136
Number dead after 5 years 630 335 256
Number dead after 10 years 964 454 397
Number receiving primary transplant at 1 year — 309 520
Number receiving primary transplant at 5 years — 516 662
Number dead before transplant or on waitlist (%)* 964 309 (30.9) 112 (11.2)
Mean cost to prevent 1 pretransplant death (2002 US
dollars)
— 122,516 199,942
Number dead after transplant (%) — 145 (14.5) 285 (28.5)
Living donor deaths (%) — — 2 (0.2)
Living donor serious complications, excluding deaths (%) — — 17 (2.4)
NOTE: Results are presented from a 120-month Monte Carlo simulation of 1000 theoretical subjects with base case values for
all variables.
Abbreviations: DDLT, deceased donor liver transplantation; LDLT, living donor liver transplantation; QALY, quality-adjusted
life year.
*This represents a 10-year cumulative mortality for the entire cohort. The yearly mortality rate on the waiting list is roughly
one-tenth of this value.
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Costs, Utility, and Cost-Effectiveness Analysis
Cost-effectiveness analysis results for the baseline case
are summarized in Table 5 for each treatment strategy.
Per-person costs for the DDLT-only cohort were
$87,000 more than those for nontransplant care. The
LDLT approach was $64,000 more expensive than the
DDLT-only approach. The increased cost of the LDLT
strategy was due to fewer waitlist deaths and thus more
ongoing posttransplant expenses in the survivors as
well as donor procedures and complications (see Fig. 2
for cost details).
Effectiveness is reported as quality-adjusted life
years (QALYs). The no-transplant strategy offered a
quality-adjusted expected survival of 2.0 QALYs, while
DDLT-only offered 4.4 QALYs. The combined LDLT
strategy resulted in 4.9-QALY expected survival, which
was 0.5 QALYs more than the DDLT-only strategy.
Cost-effectiveness ratios are reported in dollars per
QALY. The LDLT strategy yielded the highest cost per
QALY. Both transplant approaches were more effective
and reasonably priced in comparison with pure sup-
portive care/medical management of cirrhosis. The
DDLT-only strategy cost an average of $35,976 per
QALY over medical management, whereas the availabil-
ity of the LDLT strategy cost $47,693 per QALY. LDLT
quality-adjusted survival was hindered by donor mor-
bidity and, to a lesser extent, donor death. The incre-
mental cost-effectiveness ratio (ICER) of moving from
the DDLT-only strategy to the LDLT strategy was ap-
proximately $106,788 per QALY.
Sensitivity Analysis
One-way sensitivity analyses were performed on all
variables in the model. The basic relationships between
DDLT and LDLT and cost effectiveness were not af-
fected by any clinically relevant range of values for any
single variable in the model. Repeated analyses using
extreme estimates for each of these variables did not
change the preferred treatment strategy with respect to
cost effectiveness (see Fig. 3). In general, improvement
in pretransplant variables decreased the cost effective-
ness of both forms of transplantation in proportional
amounts. Conversely, improvements in posttransplan-
tation variables moderately improved the cost effective-
ness of both forms of transplantation. There were no
circumstances in the sensitivity analysis that enabled
LDLT to be less costly than DDLT and only with extreme
assumptions could their costs approach equality (see
Fig. 4). Similarly, because of donor morbidity and mor-
tality, aggregate adjusted quality of life was always only
marginally better for LDLT than DDLT, despite the de-
crease in deaths on the waitlist. The improvement in
quality of life and decrease in costs associated with less
waitlist death in the LDLT strategy were offset by the
increased exposure of recipients to posttransplant com-
plications and costs. Because of this, there were no
realistic interventions in the model that could bring the
ICER of the LDLT strategy below $50,000 per QALY.
This remained true when DDLT waiting times were var-
ied through extreme ranges. When average waiting
times for DDLT approached 3 years, the DDLT and
LDLT strategies yielded very similar ICER values. Con-
versely, when DDLT waiting times were less than 2
months, the LDLT strategy was both less effective and
more costly than the DDLT approach.
The probability of donor death and complications af-
ter LDLT were significant influences on the cost effec-
tiveness of LDLT in the extreme cases. Because of the
improved overall recipient quality of life after transplan-















No transplant 63 — 2.0 — $32,969 —
Listed for DDLT 150 87 4.4 2.4 $34,648 $35,976
Listed for DDLT with LDLT available 214 64 4.9 0.5 $43,487 $106,788
NOTE: Expected costs are those expected for a subject entering the treatment strategy arm, including all outcomes and
complications in year 2002 US dollars. Effectiveness (survival) is expressed in QALYs.
Abbreviations: DDLT, deceased donor liver transplantation; ICER, incremental cost-effectiveness ratio; LDLT, living donor
liver transplantation; QALY, quality-adjusted life year.
Figure 2. Mean costs per patient for each treatment strategy
by phase of simulation. Costs are reported in 2002 US dollars
with standard deviations. The addition of LDLT to a trans-
plant program significantly decreases pretransplant costs but
increases posttransplant and peritransplant costs. Abbrevia-
tions: DDLT, deceased donor liver transplantation; LDLT,
living donor liver transplantation.
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tation and diminished waitlist death rates, donor death
had only a marginal influence on aggregate quality of
life and adjusted survival. Only when donor death rates
exceeded an unrealistic 24% was the aggregate ad-
justed survival after LDLT less than that of DDLT. Do-
nor morbidity had little effect on overall adjusted sur-
vival and quality of life, although costs were significant.
Because of a steep learning curve in performing the
LDLT procedure,31 data regarding complications and
outcomes were separately analyzed with a cutoff of 20
LDLT procedures or fewer per center. The assumption
was that less experienced centers would have more
complications and therefore the cost effectiveness of the
procedure would improve after the learning curve was
overcome. Despite significant improvements in some
complications, cost effectiveness in experienced centers
was only minimally improved because the fundamental
costs involved with more exposure to the posttrans-
plant health state were not significantly affected.
Hepatocellular carcinoma is one circumstance that
may benefit by earlier transplantation. In the present
model, if more than 40% of waitlisted subjects have
HCC, then the ICER of LDLT approaches the commonly
accepted $50,000 per QALY but at the cost of a 17%
increase in waitlist death (282 versus 331), mainly in
the non-HCC subjects. More comprehensive simula-
tions focused specifically on HCC have been published
elsewhere.48
The cost-effectiveness measurements of all treatment
strategies in the model were highly sensitive to the time
horizon (ie, the total observation time for each subject
entering the model) chosen for the analysis. Because
the majority of expense and morbidity occurs early in
the course of liver transplantation, the major cost and
Figure 3. Sensitivity of the model to cost variables. The number shown is the percentage of cost-dependent model variability
attributable to the listed cost as determined by a tornado diagram sensitivity analysis. Within the ranges of the sensitivity
analysis, none of the cost variability was able to change the fundamental cost effectiveness of the treatment strategies. See the
text for details. All values listed as 0.0 were not statistically significant contributors to overall model variability. Abbreviations:
DDLT, deceased donor liver transplantation; HCC, hepatocellular carcinoma; LDLT, living donor liver transplantation; SBP,
spontaneous bacterial peritonitis; TIPS, transjugular intrahepatic portosystemic shunt. [Color figure can be viewed in the online
issue, which is available at www.interscience.wiley.com]
Figure 4. Two-way sensitivity
analysis of costs of individual
transplant procedures. Only un-
realistic differences in the cost
of the individual procedures
would swing the cost-effective-
ness superiority to LDLT. See
the text for details. Abbrevia-
tions: DDLT, deceased donor
liver transplantation; LDLT, liv-
ing donor liver transplantation.
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quality of life benefit of liver transplantation is in the
long-term survival advantage offered by either form of
liver transplantation. In the present model, at the
1-year observation time (from presentation for evalua-
tion with decompensated cirrhosis), neither form of
liver transplantation is cost-effective (the ICER of DDLT
was greater than $2,252,000 per QALY, whereas LDLT
was more costly and had lower survival). With a 2-year
time horizon, this trend continued (the ICER of DDLT
was greater than $513,000 per QALY, and LDLT was
still inferior). Only with a total observation period of 9
years or more does the DDLT strategy become cost-
effective with an ICER less than $50,000 per QALY,
whereas the ICER of the LDLT strategy remains greater
than $135,000 per QALY. Because the mean survival of
liver transplant recipients is greater than 10 years in
the United States, a time horizon of 10 years was cho-
sen in this model. This idea of accepting early increases
in costs and morbidity for a long-term benefit are crit-
ical in policymaking decisions about liver transplanta-
tion. Conversely, earlier transplantation would be ex-
pected to be a cost-effective treatment method only in
candidates with a high likelihood of death in the short
term. Other researchers have estimated a threshold of
survival benefit of liver transplantation to be above a
Model for End-Stage Liver Disease score of 17.61
DISCUSSION
This simulation measures the cost effectiveness of
LDLT combined with the existing standard-of-care
DDLT strategy for the treatment of end-stage liver dis-
ease using a Markov decision analysis model to simu-
late the major events that occur before, during, and
after both LDLT and DDLT. Unlike many previous mod-
els, extensive consideration was given to costs related
to the workup of potential donors that are eventually
deemed ineligible for donation, the real impact of donor
mortality and morbidity, and the effect on quality-ad-
justed survival and quality of life related to donor com-
plications. The course of chronic liver disease and liver
transplantation simulated by the model closely approx-
imates the course of events reported in the literature.
We have found that liver transplantation is an expen-
sive but effective treatment for end-stage liver disease
and cirrhosis. The ICER for the standard-of-care DDLT-
only approach was more than $35,000 when measured
over a 10-year time frame. Although modestly more
effective, mostly because of less time spent on the wait-
ing list for transplantation, the addition of LDLT to the
DDLT approach was an expensive but effective alterna-
tive. The ICER of the LDLT strategy was approximately
$106,000. The interpretation of an ICER based on a
simulation is a subjective matter and is influenced by
societal willingness to pay and by the validity of the
model and its assumptions.62 Previously reported IC-
ERs for routinely performed medical interventions in
the United States include $86,362 for screening for
colorectal cancer in people over age 65,63 $8000 to
$900,000 (depending on age and type of drug used) for
the treatment of hypertension,64,65 $112,000 for
screening for HCC in cirrhosis patients with ultrasound
and alpha fetoprotein,66 and more than $708,000 for
intravenous proton pump inhibitor therapy for peptic
ulcers.67 In contrast, the traditional willingness to pay
benchmark in the United States is based on the cost of
chronic ambulatory hemodialysis.68-70 Although an
ICER of less than $50,000 has been traditionally ac-
cepted as a cost-effective addition to the medical system
in the United States, some authors have argued that
based on different economic calculations and assump-
tions, a cost-effective medical intervention could range
from as little as $24,000 to as much as $428,000 per
QALY.71 In fact, if cost-effectiveness values associated
with hemodialysis derived from studies in the late
1980s are adjusted for year 2004 US dollars, an ICER of
$75,000 may be a more proper benchmark for modern
cost-effectiveness analyses.
All cost-effectiveness studies based on modeling have
some inherent weaknesses. Ultimately, the quality of
the model output and its resulting analysis is depen-
dent on the quality of the model, its approximation of
reality, and its probabilities, utilities, and costs used for
the calculations. In the design of the current model, we
have taken extreme care in designing a model that is
flexible yet adequately represents most of the major
events in chronic liver disease and liver transplanta-
tion. Although quite complex, the model is an approxi-
mation of reality and cannot truly represent all the
possible outcomes in this complicated disease process.
However, we have based the probabilities and health
state utilities on the best available and most pertinent
data. We agree that much of the reported literature may
be biased in one way or another, but we have attempted
to represent average reported values and used wide
ranges in the sensitivity analysis when the data were
insufficient or weak. Finally, when no published data
were available, expert opinion and unpublished data
were used, but these occurrences were few, and the
following sensitivity analyses were conducted over a
broad range.
Cost data were center-specific and this inherent
weakness was unavoidable in this simulation. Using
strong microcosting algorithms and averaging several
years’ adjusted costs minimized this inherent weak-
ness. The wide range of all costs (50%-200%) used in
the sensitivity analysis also helped guard against inac-
curate cost data. In the analysis, the costs yielded from
this model are consistent with other published cost
data in the literature. There have been 2 published
analyses from US universities assessing costs in the
setting of LDLT and DDLT.7,8 These studies published
not specific costs but related comparative costs on the
basis of cost units. Despite this, the costs related to
LDLT and DDLT in those reports were comparable to
those used in this model. Similarly, European studies
have published abridged cost data,25 and after we ac-
counted for currency conversion rates and inflation, the
costs in this model compare similarly.
We chose a 10-year time horizon because data for
transplantation in the modern era are available for ap-
proximately the last 10 years. It was also felt that ex-
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trapolating beyond 10 years with event rates was very
speculative and potentially inaccurate. This time frame
also yields a reasonable time frame to judge the benefit
of transplant beyond the immediate postsurgical com-
plications and waiting list morbidities. Also the A2ALL
study period was roughly 10 years as initially funded.
In theory, a longer time frame of observation could
change our eventual conclusion concerning cost effec-
tiveness, although no solid data are available at the
present time to support this speculation, and there is
no clear advantage to LDLT or DDLT in this respect.
Changing the overall time horizon in the model has two
opposite effects: (1) shortening the length of time that
candidates are exposed to waiting list mortality and (2)
shortening the extension of life in the posttransplant
phase that successfully transplanted candidates are
allowed to experience. These opposite effects cause a
waiting list mortality decrease at the same time as a
decrease in posttransplant quality of life benefit. The
overall effect on the model is not strong unless very
short time horizons are used. Thus, we chose the 10-
year time frame to simulate reality as much as possible
while still using data that were dependable. Another
unexplored factor in this article is regional variation in
donor utilization and organ allocation. This model as-
sumes a national distribution of organs,and the funda-
mental data in this article are based on national aver-
ages. Regional variation is a potential source of widely
variable practice in the United States, but an investiga-
tion of regional changes in cost effectiveness and LDLT
practice is beyond the scope of this article. It was the
goal of this analysis to combine the representative data
from a national sample of transplant programs in order
to give a broad view of the practice of LDLT in the United
States.
In summary, this article presents an extensive cost-
effectiveness model simulating chronic liver disease
and cirrhosis with treatment options including the
standard-of-care DDLT-only strategy and the addition
of LDLT to the treatment paradigm. Considering living
donor costs, morbidity, mortality, and quality of life,
this is the first model to accurately account for the true
consequences to the donor in the LDLT treatment strat-
egy. When traditionally defined standards of cost effec-
tiveness were used, the DDLT-only approach proved to
be a cost-effective treatment for cirrhosis with an ICER
of approximately $50,000 per QALY. However, LDLT in
combination with DDLT proved to be modestly more
effective but much more expensive than the DDLT-only
strategy per QALY saved. This simulation, along with
the decision analysis model, should be a useful tool for
policymakers and transplant centers in allocating re-
sources and guiding further investigation into the field
of cirrhosis and liver transplantation.
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